Background. Advances in next-generation sequencing (NGS) technologies allow comprehensive studies of genetic diversity over the entire genome of human cytomegalovirus (HCMV), a significant pathogen for immunocompromised individuals.
Human cytomegalovirus (HCMV) contributes significantly to morbidity and mortality in immunocompromised patients, especially after transplantation, as well as in congenitally infected children. Primary HCMV infection or reactivation of latent HCMV can result in acute illness with end-organ manifestations such as retinitis, hepatitis, pneumonitis, or enterocolitis [1] . The frequency and severity of HCMV disease in transplant recipients is influenced by risk factors such as donor (D) and recipient (R) HCMV serostatus or antiviral prophylaxis [2, 3] .
Human cytomegalovirus (species Human betaherpesvirus 5) has a double-stranded DNA genome of approximately 236
kbp containing >170 open reading frames (ORFs) encoding functional proteins [4] . Most of the genome exhibits little variability among strains, although several hypervariable genes exist; in addition, recombination contributes to HCMV variability [5] [6] [7] [8] [9] [10] [11] [12] . The picture of HCMV diversity within an individual host is complicated by the fact that prior infections with multiple strains, de novo infections, and reactivation of latent virus can occur. The role of genome variation in HCMV pathogenesis is not well understood [13] [14] [15] , although numerous studies have tried to characterize HCMV diversity and its clinical impact by polymerase chain reaction (PCR)-based genotyping of selected ORFs [16] [17] [18] .
The high resolution provided by next-generation sequencing (NGS) has made it possible to study diversity across the entire HCMV genome [4, 8, 12, 19] . Several groups have applied NGS approaches to sequencing whole HCMV genomes, albeit mostly using cell-culture passaged isolates or amplicon sequencing [6, 10, 12, [20] [21] [22] . Here, we used a target enrichment approach to sequence directly from clinical samples because this offers the advantage that the sequences obtained are more likely to represent accurately the original viral population than those obtained by using previous approaches [23] . We present an analysis based on sequence data obtained from sequential time points or different anatomical compartments from 20 HCMV-infected, immunocompromised patients.
METHODS

Patients and Specimens
A total of 68 archival, HCMV-positive clinical specimens were obtained from 20 patients for which real-time quantitative PCR (qPCR) for HCMV had been requested: whole blood (n = 49), plasma (n = 5), urine (n = 3), breast milk (n = 2), vitreous humor (n = 1), tissue biopsies (n = 4; from gut or liver), or respiratory material (n = 4). Samples originated from 4 children with (congenital) HCMV disease (including breast milk from 2 of the children's mothers), 8 renal transplant recipients (RTRs), and 8 hematopoietic stem cell transplant recipients (SCTRs). For 15 of 20 patients, blood samples obtained longitudinally at various time points were available (2-8 time points per patient; median = 120 days [range = 17-383] between first and last samples). Clinical data were retrieved from medical records. This descriptive study was approved by the institutional review board of Hannover Medical School (no. 2527-2014). Table 1 shows an overview of patient demographics, clinical data, and sample types.
Human cytomegalovirus monitoring by qPCR (or pp65 antigenemia assay) was performed according to the procedures followed in individual transplant units. Antiviral treatment with ganciclovir, foscarnet, or cidofovir and, in a few cases, maribavir, leflunomide, or donor lymphocyte infusions was given at the physicians' discretion (preemptively or triggered by signs or symptoms of HCMV infection). Renal transplant recipients usually received antiviral prophylaxis depending on the risk constellation.
Nucleic Acid Extraction and Viral Load Quantitation
Extraction of DNA from 200 µL of clinical material and HCMV qPCR (calibrated to the World Health Organization standard; limit of detection 500 IU/mL) were performed as described previously [24] . The HCMV genome input concentration was calculated as IU (international units; approximately equivalent to genome equivalents) per sequencing library.
Next-Generation Sequencing
DNA was sheared by sonication, and sequencing libraries were prepared (KAPA library preparation kit, KAPA Biosystems) as previously described [25] , with a few modifications. Briefly, fragmented DNA was end repaired, A tailed, and ligated to NEBnext Illumina adaptors (New England Biolabs). After PCR preamplification (6-14 cycles), up to 750 ng of DNA was target enriched for HCMV fragments (SureSelect XT kit, Agilent). RNA probes for the bait library were designed on the basis of 64 complete HCMV genome sequences available to us in April 2014 (details available from A. Davison). Human cytomegalovirus enriched libraries were indexed using TruGrade oligonucleotides (Integrated DNA Technologies), amplified (KAPA real-time library amplification kit), multiplexed, and sequenced on a MiSeq (Illumina) using reagent kit v3 to generate 2 × 300 base paired-end reads.
Assembly of Human Cytomegalovirus Genome Sequences
Bowtie2 v2.2.6 [26] was used to map reads to the UCSC hg19 human reference genome, and these reads were then discarded. The remaining reads were subjected to quality assessment and adaptor trimming using FastQC and Trim Galore v0.4 (http:// www.bioinformatics.babraham.ac.uk/projects), retaining reads of quality score ≥20 and length >130 bp. Contigs were assembled de novo by using SPAdes v3.6 [27] and ordered against a version of the HCMV reference strain Merlin genome (GenBank AY446894.2) lacking the long and short terminal repeats (TR L and TR S ) by using Scaffold_builder [28] , abacas [29] , or CLC Genomics Workbench v8 (Qiagen, https://www. qiagenbioinformatics.com/). Gaps were closed (GapFiller v1-10 [30] ), potential assembly errors were corrected by iterative mapping (ICORN2 [31] ), and genome annotations were transferred from HCMV strain Merlin (RATT [32] ). Subsequent analyses were performed by using the resulting sample-specific consensus sequences ("major genome type"), lacking TR L and TR S , having assessed sequence quality by careful inspection of read alignments. The presence of multiple HCMV strains in the original specimen that likely arose by independent infection events (whether by coinfection, serial infection, or reactivation) was assessed initially by mapping reads against the genotype-specific sequences of selected hypervariable genes (UL73, UL74, UL139, and UL146) characterized previously from a wide range of independent patients [5, 8, 33] (data not shown) and subsequently by calculating the level of nucleotide diversity by variant analysis. A control experiment was performed to validate this protocol (Supplementary Figure 1) .
Selected complete HCMV genome sequences from patients infected by a single strain were deposited in GenBank (KY123649-KY123653).
Phylogenetic Analysis
A multiple sequence alignment of sample-specific consensus sequences was constructed (MAFFT v7 [34] ). A neighbor-joining tree was constructed by using MEGA6 [35] , applying the Kimura 2-parameter method with 500 bootstrap replicates and complete deletion of gapped sites. Overall mean distance and pairwise distance comparisons (p-distance) were performed (MEGA6) with 1 representative sample from each patient (n = 20) or the whole dataset (n = 57) with complete deletion of gapped sites.
Variant Analysis
Duplicate reads presumably resulting from >2 PCR-derived copies of the same HCMV DNA fragment were removed from each dataset by using Picard v2.3.0 (https://github.com/ broadinstitute/picard). Variants (single nucleotide polymorphisms and insertions/deletion) were identified by using the low-frequency variant detector function in CLC Genomics Workbench. The dynamics of variants over time were tracked by aligning sequence reads from different time points from a patient against the consensus sequence from the initial time point and performing variant calling. Variants were considered valid under the following conservative criteria: overall read depth ≥50, average basecall quality ≥20, forward/reverse read balance 0.3-0.5 and variant frequency ≥2% (ie, the relative frequency of a variant at a particular position). Variants detected within homopolymer regions or internal repeats (IR L /IR S ) were excluded. Variants were plotted using custom R scripts by position in the HCMV genome and frequency at each time point. Variants present at >50% were taken to indicate a switch in the major HCMV genome type compared with the initial time point. In addition, the frequency distribution of variant alleles was visualized in frequency histograms.
Antiviral resistance mutations were identified by using published definitions [36] .
RESULTS
Next-Generation Sequencing of Human Cytomegalovirus Directly From Clinical Specimens
To characterize HCMV diversity among samples collected sequentially or from different anatomical compartments, NGS was performed on DNA extracted from a set of 68 different clinical specimens from 20 immunocompromised patients by using target enrichment. The median HCMV input per library was 1.8 × 10 4 IU (range = 1.0 × 10 3 to 9.5 × 10 5 ) for whole blood and 1.1 × 10 5 IU (range = 5.0 × 10 2 to 3.9 × 10 6 ) for other specimens. The range of percentage of HCMV reads in the enriched libraries was 0.03%-88.8%. Consensus HCMV genomes were assembled from 57 sequenced samples, achieving an average coverage of 99.94% (range = 98.67%-100%). An average read depth was obtained of 17-5450 (median = 359) for whole blood and 113-5663 (median = 2932) for other specimens. Assembly of consensus sequences for 9 whole blood samples and 1 breast milk sample was not feasible due to low coverage, probably because of low HCMV input (range = 5.0 × 10 2 to 1.8 × 10 4 IU per library). Assembly of data from 1 blood sample failed due to infection with 2 strains in approximately equal proportions.
Interstrain Diversity and Phylogenetic Analysis of Major Human
Cytomegalovirus Genome Types
The average interstrain nucleotide diversity calculated from the consensus sequence of 1 sample from each patient was 0.022 (ie, any 2 HCMV strains differed by an average of 2.193%). Phylogenetic analysis of all sample-specific consensus sequences obtained longitudinally or from different compartments (Figure 1 ) sorted the patients into 2 groups: those in whom 1 genome type was consistently dominant (Child1, Child2, Child3, Child4, RTR2, RTR4, RTR5, RTR9, RTR10, RTR11, SCTR2, SCTR4, and SCTR12) and those in whom the dominant genome type switched during the course of infection (RTR6 among 2 compartments, and RTR1, RTR3, SCTR1, SCTR3, SCTR8, and SCTR11 among sequential samples). In the latter group, nucleotide diversity between the initial and final time points was 0.008-0.026, indicating that in some patients the HCMV population after the switch differed from that before the switch to a similar extent to HCMV strains in 2 different individuals (Table 1 ). 
Genetic Diversity Among Longitudinal Samples
The different clustering patterns of consensus sequences obtained from the same patient prompted an investigation of the level of within-host diversity for samples with sufficient read depth. For each patient, the HCMV population diversity was assessed by mapping the read data from each sample against the consensus sequence from the initial time point. Various patterns of within-host diversity were apparent (Table 1) .
A switch in the major genome type over time was observed in 6 of 15 patients-for example, in SCTR1 at day 224 after transplantation, with the ultimately dominant genome type being detectable at low frequency in the initial sample at day 91 ( Figure 2 ). In this sample, a multiple infection was detected by variant analysis of the initial time point dataset against its own consensus sequence: 3982 intrahost variants with a median frequency of 7% (range = 2%-25%) were detected. In the second blood sample (sampled 35 days later) and in the last blood sample, the median variant frequency increased to 36% (range = 2%-46%) and 83% (range = 5%-100%), respectively. Similarly, a complete switch of the major genome type between the first and last samples was observed in SCTR11 within 104 days (Supplementary Figure 2) . In SCTR8, 4284 (median frequency = 8%; range = 2%-29%) and 6661 variants (median frequency = 52%; range = 2%-98%) were present at the initial and last time points, respectively. Interestingly, these variants segregated into 2 clusters, with a frequency range of 25%-62% and 85%-95%, respectively (Figure 3) . This indicated the emergence of a new dominant genome type at the second time point (which was already detected at the initial time point at low frequency) accompanied by an additional (minor) population perhaps arising due to reactivation. One or more of these additional populations may have been donor derived in view of the D+/R+ serostatus constellation.
Changes of the dominant HCMV genome type in patients RTR1, RTR3, and SCTR3 were also observed, with nucleotide diversity values between the initial and final time points of 0.011, 0.019, and 0.008, respectively. However, because of low read depth in some samples, variant analysis could not always be interpreted with confidence. Nevertheless, based on the consensus sequence analysis, RTR1 showed an unusal diversity pattern among samples collected from 2 major reactivation episodes, with major differences in particular within the RL11 gene family (which contains several hypervariable members) and the US6 gene family, these regions being reminiscent of sequences contributed by independent strains (Figure 4 ). This suggests that the genome type emerging in the second reactivation episode (day 380 after transplantation) may have resulted from intrahost recombination or from reinfection with or reactivation of a closely related strain.
Finally, switches in the major genome type were not detected in the other 9 patients with longitudinal samples ( Supplementary  Figure 3) , although some contained minor populations indicating multiple strain infections (Supplementary Figure 4) .
Human Cytomegalovirus Diversity Between Anatomical Compartments
The major HCMV genome types from different anatomical compartments in the same patient were highly similar or identical to each other in blood and urine (blood and bronchoalveolar lavage in 1 case). These patients included the congenitally infected children (including a corresponding breast milk sample from 1 mother) and most of the transplant recipients (Table 1) . However, similar to the situation in sequential blood samples, minor populations likely corresponding to multiple strain infections were detected in a few patients.
One impressive exception was patient RTR6, who suffered from full-blown HCMV retinitis occurring 8 years after renal transplantation. The major HCMV genome type from vitreous humor demonstrated major differences in comparison with the corresponding blood compartment. Using the consensus genome from blood as a reference, a total of 1000 variants (frequency = 2%-100%; median = 84%) were detected in the vitreous body compartment ( Figure 5A and 5B). A total of 731 variants were present at >50% (nonsynonymous = 145, synonymous = 435, and noncoding = 151) and located mostly in the region containing genes UL69-UL99 ( Figure 5C ). Generally, synonymous substitutions were more common than nonsynonymous ones, although UL73 (glycoprotein N) and UL74 (glycoprotein O) displayed high levels of nonsynonymous substitution.
Antiviral Resistance Mutations
A total of 8 of 15 longitudinally sampled patients showed mutations associated with HCMV antiviral resistance in at least 1 sample, in either or both of genes UL54 or UL97. Child4, RTR4, RTR9, and RTR10 did not exhibit resistance mutations initially but developed UL97 mutations later (Table 1) , whereas RTR3 showed a low-frequency resistance mutation in UL97 (16%) at the initial time point, which later became dominant (68%). SCTR11 and SCTR1 developed low-frequency resistance mutations (<40%) in UL54 in blood after a switch of the dominant HCMV population. Interestingly, a dominant UL54 resistance mutation (Glu756Gln) was detected in a gut biopsy from SCTR1 at day 244 (76% frequency), compared with the corresponding blood sample (39% frequency). In RTR1 (D+/R−), who underwent antiviral prophylaxis, UL97 resistance mutations were already present initially (day 166) but were lost by day 235 when the patient exhibited UL54 resistance mutations (foscarnet treatment had been started at day 186). After antiviral treatment (2 cycles of cidofovir, followed by ganciclovir/valganciclovir), this patient became negative for HCMV DNAemia, and, in the second reactivation episode at day 472 (no antiviral treatment at this time), no signs of UL54 or UL97 resistance were detected, suggesting emergence of another HCMV genome type or re-emergence of the parental genome type from the latent repository as a result of selection against the resistance mutants in the absence of drug selection.
DISCUSSION
Because of the low abundance of HCMV DNA in many clinical specimens, most NGS-based studies analyzing the whole HCMV genome have involved sequencing strains isolated in cell culture or amplicons generated by PCR. Here, we sequenced HCMV directly from a variety of clinical specimens using a commercial target enrichment approach that has been applied previously to several pathogens, including herpesviruses and HCMV [12, 37, 38] . Our carefully designed bait library, which included multiple viral genotypes, proved key to success because this enabled us to cope with the full range of genome variation and obtain adequate read depths throughout the genome. Also, adaptations of standard library preparation techniques [25] enabled us to sequence complete HCMV genomes even for specimens with relatively low viral loads and high human genomic backgrounds (eg, whole blood). Current limitations of the method include relatively high costs and a limit of detection to yield complete HCMV genomes (here approximately 5000 IU/library for whole blood). In addition, low sequencing depth due to low viral input may hamper detailed variant analysis. The latter limitations can prove difficult for investigations using whole blood samples from transplant recipients because high HCMV DNAemia is observed only in severe cases or after development of antiviral resistance.
We obtained whole HCMV genomic data from 57 clinical specimens from 20 patients. Levels of interstrain diversity were similar to those estimates proposed previously [10] . Analysis of longitudinal HCMV diversity in blood samples showed a switch in the dominant HCMV population in 6 of 15 individuals. It is likely that these patients had multiple strain infections, and in most cases the strain that became dominant by the final time point was already detectable at the initial time point by variant analysis. A switch is probably due to a change in the relative levels of replication of strains in the multiple infection, as suggested by a study based on HCMV genotyping in lung transplant recipients [33] . An alternative explanation would be de novo infection.
Patients with a longitudinal strain switch had a slightly longer observation time (Mann-Whitney test, P = .01) but no higher mortality than patients lacking a switch. It is unclear whether the former difference (likely due to the presence of resistance or prolonged, severe disease courses in high-risk patients) might have facilitated the detection of a switch or, alternatively, whether a switch is more likely to lead to prolonged, and potentially more severe, episodes of HCMV DNAemia. The latter hypothesis is supported by previous studies on clinical outcome in immunocompromised patients that show that multiple infections can be associated with higher viral loads, delayed clearance, and increased HCMV disease rates, graft rejection, and coinfections with other herpesviruses [16, 18, 39] . Multiple strain infections are common after transplantation (15%-90%), and often found in the D+/R+ and, consistent with data from our cohort, D+/R− or D−/R+ patients because both donor and recipient may have accumulated multiple strains before transplantation [15] .
Longitudinal changes in the HCMV population might contribute to pathogenesis-for example, through differential properties conferred by polymorphisms in viral glycoproteins, many of which are hypervariable and are known to contribute to immune evasion via antigenic variation [40] . In 4 of 6 patients showing a marked change of the HCMV population over time, the ultimately dominant genome type encoded variants of glycoprotein and immunomodulatory genes different from the initially dominant type. In contrast, the diversity observed upon a switch of the dominant population in RTR1 and SCTR3 was mostly observed only in genomic regions associated with immunomodulatory functions, which is more consistent with intrahost recombination events. Detection of these different patterns highlights an advantage of sequencing clinical material directly, rather than cell culture isolates, which, during passaging, tend to accumulate variations and mutations in certain glycoprotein and immune evasion genes [6, 8, 41] .
From the analyses of HCMV population diversity among anatomical compartments, general compartmental differences in congenitally infected children and most of the transplant recipients were not observed. Recent studies on HCMV diversity in urine and blood from congenitally infected children have reported that multiple strain infections or compartmentalization between blood and urine are rarely detected in these patients [21, 42] . One exception in our study was patient RTR6, suffering from HCMV retinitis, who showed a remarkable diversity in the region encoding genes UL69-UL99, with glycoproteins gO (UL74) and gN (UL73) displaying the highest levels of nonsynonymous substitutions. These glycoproteins play important roles in tissue tropism and protect the virus from neutralizing antibodies [40, 43] . The presence of HCMV genotypes encoding different gB glycoproteins in vitreous humor and blood has been reported previously for AIDS patients with retinitis [44] . The mechanism of compartmentalization is not well understood but could be attributed to selection of a particular strain (due to cellular tropism), bottlenecking of the viral population in the eye, or de novo infection [45] . Antiviral resistance of HCMV is a severe clinical problem, especially for transplant recipients [46, 47] . In our study, 8 of 20 patients showed signs of UL97 or UL54 resistance mutations. In SCTR1, we observed the presence of a dominant UL54 resistance mutation in a gut biopsy but not in the corresponding blood sample. Such a compartmentalization of drug-resistant HCMV has been reported previously as characterizing cerebrospinal fluid and blood in SCTRs [48, 49] . Although this was not the main aim of our study, NGS facilitates data mining in an unbiased fashion and allows the detection of low frequency events that are usually not detectable by Sanger sequencing. These advances could facilitate earlier detection of known resistance markers in patients at risk or novel mutations that are currently not accessible to routine diagnostics [50] .
Our data show that the NGS of HCMV directly from a variety of diagnostic specimens is feasible and informative, providing new insights into viral diversity in longitudinally sampled patients. We found evidence of a switch of the major genome type in nearly half of the transplant recipients analyzed, suggesting that recurrent HCMV DNAemia after transplantation does not necessarily reflect reappearance of the previously replicating strain but rather the emergence of additional strains, possibly with variant biological properties, that were already present or acquired subsequently. This phenomenon could influence the development and course of HCMV disease, although it did not correlate with a fatal outcome in our relatively small patient cohort. Further investigations of the global variability patterns observed in clinical samples, as well as of the role of intra-host recombination and functions of variants of key viral genes, are necessary to elucidate the role of HCMV diversity in pathogenesis.
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